On the other hand, short term treatment with high dose CTLA-4Ig (abatacept), which has been shown to have anti-inflammatory properties in arthritis, leads to a precipitous loss of CD4+CD25high regulatory T cells and, in some animal models, exacerbation of autoimmunity [160]. This evidence concerns the gene CD4 and arthritic joint disease.